Business Wire

IA-WORKIVA

25.5.2021 09:02:09 CEST | Business Wire | Press release

Share
The Power of Transparency: Individual Investors Demand ESG Data They Can Trust

Workiva Inc. (NYSE:WK) today released findings from a survey of individual investors that reveal approximately 70% of respondents believe organizations have a responsibility to demonstrate ESG performance to investors, with Gen Z and younger Millennial-aged investors (18-34 year-olds) the most demanding around ESG credentials. The survey revealed transparency around ESG disclosures is becoming integral to investor decisions, and companies will undoubtedly experience increased pressure from investors to be able to report on their progress.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210525005313/en/

“Our survey findings represent a powerful motivation for organizations to take a serious look at how they are reporting ESG and other non-financial data,” said Julie Iskow, chief operating officer of Workiva. “We believe there is a real competitive advantage in attracting today’s modern investors with a commitment to corporate transparency.”

Top Survey Trends:

Younger Investors Know What They Want . Awareness around ESG is especially high within the younger generation, with 84% being aware of ESG, and of this group nearly two-thirds (64%) claiming to know a lot about it.

  • ESG awareness was found to be most prevalent in Germany with 93% of investors under 34 years old noting they were already aware of ESG in investments.
  • In the United States 65% of Gen Z and Millennials state ESG in companies has become more important over the last year and will continue to become more important (69%) due to climate change.
  • Also, most pronounced in the U.S., 72% of 18–34 year-olds want to know whether a company lives up to their social and moral beliefs before they invest.

Difficulty in Trusting Data. When asked if they found it difficult to trust what companies are disclosing about what they’re doing for the environment and society, only 15% of respondents disagreed.

  • In addition, over 60% of respondents across all regions stated they find it difficult to judge whether companies are doing the right thing when it comes to the environment and society.

Data is the Key. Over one-third of survey respondents (43%) in all markets noted they trust ESG performance more when reported through numbers and data than qualitative descriptions — this increased to 54% for 18-34 year-olds.

  • 72% of individual investors believe that companies should make it easier for them to judge ESG efforts through data.
  • More than half of all individual investors surveyed expressed that they would be more likely to invest in a company that demonstrates its ESG performance. This sentiment increased to 60% for Gen Z and Millennial-aged investors across all regions.

This survey of individual investors comes on the heels of large institutional investors and asset managers extolling the benefits of integrating ESG metrics as a key factor in building their investment portfolios, as well as trends in new regulations requiring non-financial reporting.

“The survey indicates that investors want to see earnings growth, deeper data transparency and progress in all areas of ESG. This will require a technology solution that can deliver accuracy and simplify the complex process of collecting and reporting non-financial data; Workiva is revolutionizing how companies approach ESG reporting with a solution that does just that,” added Iskow.

Workiva's cloud-based platform creates a connected and controlled ecosystem that streamlines the integration of financial and non-financial information. ESG and finance teams can collect, assemble and report data on one secure platform, allowing businesses to keep pace with the rapidly growing demand for trusted, transparent data and proof of ESG forward-looking business goals.

Check out the ESG Survey results or learn more about Workiva’s purpose-built ESG reporting solution .

About the Survey

Workiva commissioned a survey to better understand the current sentiment of individual investors (who have grown in importance and activity1 ) on the transparency and faith in ESG performance and reporting data. The survey findings cover individual investors from the United States, United Kingdom, Germany and France. Read our Fact Sheet for methodology and specific question responses.

1. Individual investors made up an estimated 19.5% of U.S. equity trading volume according to Bloomberg Intelligence, a jump of over 4% compared to 2019.

About Workiva

Workiva Inc. (NYSE: WK) simplifies complex work for thousands of organizations worldwide. Customers trust Workiva’s open, intelligent and intuitive platform to connect data, documents and teams. The results: improved efficiency, greater transparency and less risk. Learn more at workiva.com.

Request a Workiva demo: www.workiva.com/request-demo
Read the Workiva blog: www.workiva.com/blog
Follow Workiva on LinkedIn: www.linkedin.com/company/workiva
Like Workiva on Facebook: www.facebook.com/workiva/
Follow Workiva on Twitter: www.twitter.com/Workiva
Follow Workiva on Instagram: www.instagram.com/workivalife

Link:

ClickThru

Social Media:

https://www.facebook.com/workiva/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Strongest Half-Year in Curatis’s History — Revenue up 51% and Significant Progress on Corticorelin (C-PTBE-01)21.9.2026 07:03:00 CEST | Press release

Curatis Holding AG (SIX:CURN, “Curatis”) reports net sales from goods and services of CHF 7.9m for the first half of 2026, up 51% (H1 2025: CHF 5.2m), with the loss for the period narrowing to CHF -0.4m (H1 2025: CHF -1.2m) and cash and cash equivalents rising to CHF 3.6m (31 December 2025: CHF 1.9m). Curatis also advanced its corticorelin (C-PTBE-01) program on multiple levels, including an exclusive Japan licence with Neupharma and continued manufacturing progress. Business development and finances Net sales from goods increased by 46% to CHF 7.4m (H1 2025: CHF 5.0m) and net sales from services rose to CHF 0.6m (H1 2025: CHF 0.2m). Growth was driven both by products marketed for some time and by products added to the distribution portfolio in 2025 and 2026. The gross contribution from goods and services rose by 32% to CHF 1.8m (H1 2025: CHF 1.3m); the combined cost base grew by only 9% against net sales growth of 51%, as personnel expenses rose 5% to CHF 1.3m (H1 2025: CHF 1.2m) and

Galderma Begins Trading in the Swiss Market Index, Joining Switzerland's Leading Blue Chip Companies21.9.2026 07:00:00 CEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today begins trading as a constituent of the Swiss Market Index (SMI), Switzerland's leading blue chip equity benchmark comprising 20 of the country's largest and most liquid listed companies. Less than three years after its IPO on the SIX Swiss Exchange in March 2024, Galderma has established itself as one of Switzerland's leading listed companies. Its inclusion in the SMI reflects the company's strong growth, disciplined execution and increasing relevance in Swiss and international capital markets as it advances its ambition to become the world's leading dermatology powerhouse. Since its IPO, Galderma has continued to execute its growth-focused integrated dermatology strategy, delivering strong performance across Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Net sales increased from 4.410 billion USD in 2024 to 5.207 billion USD in 2025, driven by science-led innovation, portfolio and geogr

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye